When Clear Cytoplasm Isn't Enough: Napsin A and HNF1-beta in Ovarian Clear Cell Carcinoma

A 48-year-old woman presents with a pelvic mass and ascites. The biopsy shows clear cytoplasm, tubulo-cystic and papillary architecture, and hobnail nuclei — but the grade reads as ambiguous, and clear cells can turn up in more than one ovarian tumor type. This is exactly the situation where a well-chosen immunohistochemistry panel earns its place on the requisition. Getting the histotype right here isn't a bookkeeping exercise; it changes how the clinical team thinks about the tumor's expected behavior.

Napsin A and HNF1-beta are two of the workhorses in that panel. Neither is a magic bullet on its own, but together — and read against WT1 and p53 — they help pull clear cell carcinoma (CCC) out of a crowded morphologic differential.

What the test measures

Napsin A is an aspartic proteinase normally expressed in type II pneumocytes and renal tubular epithelium. In gynecologic pathology, it's most useful as a positive marker of ovarian clear cell carcinoma, where it shows granular cytoplasmic staining [2]. HNF1-beta (hepatocyte nuclear factor 1-beta) is a transcription factor that drives glycogen handling and other metabolic programs, and it localizes to the nucleus. Its upregulation is a recurrent feature of the clear cell phenotype [1].

The biological logic is that CCC arises through a distinct molecular pathway from high-grade serous carcinoma (HGSOC) — often tied to endometriosis, frequently carrying ARID1A and PIK3CA alterations rather than the near-universal TP53 mutation of HGSOC [1]. That divergence is why the immunoprofile lines up the way it does: Napsin A positive, HNF1-beta positive, WT1 negative, and p53 wild-type.

How it's tested

Both markers are assessed by immunohistochemistry on formalin-fixed, paraffin-embedded (FFPE) tissue — the same block used for routine diagnosis. Preanalytics matter more than people sometimes credit. Cold ischemic time, underfixation, and overly aggressive antigen retrieval can all blunt or distort staining, and nuclear markers like HNF1-beta are particularly sensitive to fixation quality. A weak or equivocal result on a poorly fixed specimen shouldn't be over-read.

Scoring here is interpretive rather than quantitative in the way a hormone receptor percentage might be. The question is pattern recognition: does the staining support a clear cell histotype? Napsin A gives granular cytoplasmic reactivity; HNF1-beta gives crisp nuclear staining. The panel is read as a whole. That's the important part — you're not chasing a single positive stain, you're triangulating.

What each result state means

Napsin A positive / HNF1-beta positive. In the right morphologic context, and with WT1 negative and p53 wild-type, this profile supports a diagnosis of clear cell carcinoma [1,2]. This is the constellation that resolves the ambiguous case at the top of this article.

Negative. Loss of one or both markers doesn't automatically exclude CCC, but it should prompt you to widen the differential and lean harder on morphology and the rest of the panel. A WT1-positive, p53-aberrant tumor with clear-cell change, for instance, is far more likely to be high-grade serous carcinoma with clear cytoplasm than a true CCC. The evidence suggests these markers are best used as confirmatory tools inside a panel, not as standalone gatekeepers.

What it determines for treatment eligibility

Histotype assignment is where this panel does its real clinical work — and the framing has to stay educational, not prescriptive.

Ovarian clear cell carcinoma behaves differently from high-grade serous carcinoma. The evidence indicates that CCC is generally less platinum-sensitive than HGSOC, and it tends to be managed as a distinct entity [1]. That relative chemoresistance is precisely the biological reason a confident histotype call matters to the treating clinicians: it shapes their expectations about how the tumor is likely to respond and informs which management pathways are even on the table.

The correct way to state the linkage is at the level of eligibility, not recommendation. Confirming clear cell histotype informs eligibility for the class of management approaches used for CCC rather than those tailored to HGSOC. The pathology report doesn't tell anyone what drug to take — it defines the tumor category that the multidisciplinary team then reasons from. A misclassified CCC managed on HGSOC assumptions is a real clinical risk, and that's the downstream consequence a clean panel helps prevent.

Caveats and what's evolving

A few practical cautions belong on every trainee's mental checklist.

First, Napsin A is sensitive but not perfectly so. It's not expressed in every clear cell carcinoma, so a negative Napsin A stain in an otherwise convincing CCC morphology shouldn't override the histology [2]. This is one more argument for reading it inside a panel rather than relying on any single marker to make or break the diagnosis.

Second, specificity has boundaries. HNF1-beta in particular is not exclusive to clear cell carcinoma — ovarian endometrioid carcinoma can occasionally express it, and clear-cell change can occur in several histotypes. That overlap is exactly why morphologic correlation stays central. The immunoprofile supports a diagnosis; it doesn't substitute for looking at the slide. When the stains and the architecture disagree, the discordance itself is the finding, and it deserves to be worked through rather than papered over.

Third, remember what the WT1 and p53 members of the panel contribute. WT1 negativity and p53 wild-type pattern are part of what distinguishes CCC from HGSOC, and interpreting the p53 stain correctly — recognizing true wild-type versus aberrant patterns — takes experience. A misread p53 can send the whole interpretation off course.

The bottom line

The Napsin A / HNF1-beta pairing is best understood not as a test that returns an answer, but as two coordinates in a triangulation. Read alongside WT1 and p53, and always against the morphology, they help convert an ambiguous clear-cell tumor into a confident histotype — and it's the histotype, not any single stain, that carries the clinical weight. When the panel and the slide tell the same story, you can report clear cell carcinoma with real confidence. When they don't, the panel has still done its job: it's told you to slow down and look again.

---

References

1. WHO Classification of Tumours Editorial Board. Female Genital Tumours, 5th ed. IARC, Lyon; 2020. ISBN 978-92-832-4504-9.
2. Ordóñez NG. Napsin A as a marker of clear cell ovarian carcinoma. International Journal of Gynecological Pathology; 2014. PMCID: PMC4228360.